Propranolol in schizophrenia. Clinical, metabolic, and pharmacological findings

Arch Gen Psychiatry. 1980 Jun;37(6):685-90. doi: 10.1001/archpsyc.1980.01780190083010.

Abstract

Six schizophrenic patients received propranolol hydrochloride to evaluate pharmacological, endocrinological, and antipsychotic properties of the drug. They had previously been unsuccessfully treated with phenothiazines. After a drug-free period of two weeks, propranolol was administered in gradually increasing doses. After two to four weeks, a low dose of phenothiazines was added. The clinical effect was evaluated using the Comprehensive Psychopathological Rating Scale. Three of the six patients showed a definite improvement with propranolol therapy given as a sole treatment. Propranolol in plasma was positively correlated to dosage. The proportion of its major metabolite, 4-hydroxy-propranolol, decreased with increasing drug dose. Melatonin and prolactin levels in serum decreased noticeably with propranolol treatment. When phenothiazines were added, prolactin increased above drug-free levels. These results support the view that propranolol has an antipsychotic potential that needs further evaluation in clinical trials.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Female
  • Humans
  • Male
  • Melatonin / blood
  • Middle Aged
  • Prolactin / blood
  • Propranolol / blood
  • Propranolol / therapeutic use*
  • Psychiatric Status Rating Scales
  • Schizophrenia / blood
  • Schizophrenia / drug therapy*
  • Schizophrenic Psychology*
  • Thioridazine / therapeutic use

Substances

  • Prolactin
  • Propranolol
  • Melatonin
  • Thioridazine